News

Sanofi, Vicebio

Sanofi to Buy Vaccine Developer Vicebio for Up to $1.6 Billion
The deal seeks to strengthen the drugmaker’s portfolio of respiratory vaccines and help it move on from pipeline setbacks.
Sanofi Makes $1.6B Vaccine Bet With Vicebio Acquisition
The acquisition, which will give Sanofi a combination vaccine for respiratory syncytial virus and human metapneumovirus, follows the pharma’s potential $1.4 billion COVID vaccine licensing deal with Novavax last year,
Sanofi to buy vaccine biotech Vicebio for $1.15B upfront
Sanofi is buying Vicebio for more than $1 billion, picking up an experimental vaccine targeting RSV and another respiratory bug.
Sanofi Acquires Vicebio for $1.15 Billion, Enhancing Respiratory Vaccine Pipeline
According to the terms of the agreement, Sanofi will acquire London-based Vicebio’s entire share capital for an upfront payment of $1.15 billion with milestone payments upwards of $450 million based on development and regulatory checkpoints. The deal is set to close in Q4 of 2025 and won’t drastically affect Sanofi’s financial guidance for 2025.
Sanofi to acquire vaccine biotech in billion-dollar deal
The French pharma will pay $1.15 billion upfront to buy Vicebio and gain access to non-mRNA vaccine candidates against RSV and metapneumovirus.
France's Sanofi to acquire biotech firm Vicebio for $1.15 billion
French pharmaceuticals company Sanofi said on Tuesday it would acquire British private biotechnology firm Vicebio for a total of $1.15 billion, expanding its respiratory vaccine portfolio.
Sanofi to Buy Vicebio for Up to $1.6 Billion in Vaccine Push
Sanofi agreed to buy UK vaccine developer Vicebio Ltd. for as much as $1.6 billion, as it seeks to expand in respiratory treatments.
Sanofi Expands Respiratory Vaccine Portfolio With UK Biotech Buy
Sanofi SA (NASDAQ:SNY) on Tuesday agreed to acquire Vicebio Ltd, a privately held biotechnology company headquartered in London, U.K. The acquisition brings an early-stage combination vaccine candidate for respiratory syncytial virus (RSV) and human metapneumovirus (hMPV),
Sanofi to buy Vicebio for up to US$1.6 billion in vaccine push
PARIS] Sanofi agreed to buy UK biotech Vicebio for as much as US$1.6 billion, gaining experimental vaccines and a technology to streamline their development. Read more at The Business Times.
Billion euro deal: Sanofi buys UK biotech company to expand respiratory vaccine portfolio
French pharmaceutical company Sanofi said it is acquiring London-based Vicebio to expand its range of respiratory virus vaccines and add a non-mRNA vaccine to its pipeline. View on euronews
Sanofi to acquire Vicebio in $1.6 billion deal to boost respiratory portfolio
Vicebio, a biopharmaceutical company developing novel vaccines against life-threatening respiratory viral infections, has entered an exclusive, definitive agreement to be acquired by Sanofi (NASDAQ:SNY).
Dealbreaker on MSN1d
Sanofi Extends Respiratory Vaccines Reach With $1.15B Acquisition of Clinical-Stage Vicebio
The deal complements an existing partnership with Novavax that encompasses R&D of combination vaccines for Covid-19 and flu.
Fierce Biotech2d
Sanofi tightens grip on RSV, paying $1.15B upfront for Vicebio and boosting its pipeline beyond mRNA
Sanofi has struck a deal to buy Vicebio for $1.15 billion upfront, securing preclin | Sanofi has struck a deal to buy Vicebio ...
Novavax Shares Promising Results For Bird Flu Vaccine, Tested In Primates
Novavax reports strong immune responses from H5N1 avian flu vaccine candidate, showing promise in single and two-dose ...